The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
Abstract
Key Points: Chemotherapy results in a short median time to next treatment in patients with mycosis fungoides/Sézary syndrome. α-interferon achieves a superior time to next treatment compared with chemotherapy, regardless of stage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · cited 1×
“In recent years, with the increasing interest in the role of biological agents in T-cell lymphomas, there have been moderately large studies examining the role of vorinostat, romidepsin, panobinostat, pralatrexate, denileukin diftitox, and lenalidomide in MF/SS.(24,30-34,40,53) There are also published studies of sing…”
BackgroundDuvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M. (2014) · Blood · doi:10.1182/blood-2013-09-525915 · Cited by 93 · cited 6×
“), the monoclonal antibody alemtuzumab, 36,37 and the fusion toxin denileukin diftitox 38-40 and extracorporeal photopheresis (ECP), 41 have all shown activity in MF/SS.”
BackgroundInfluential
Cited by
Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588
Self-citationTrautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., Gniadecki, R., Klemke, C.-D., Ortiz-Romero, P. L., Papadavid, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.027 · Cited by 452
Willemze, R., Hodak, E., Zinzani, P. L., Specht, L., & Ladetto, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy133 · Cited by 281
Mogamulizumab: 2 birds, 1 stone
Wilcox, R. A. (2015) · Blood · doi:10.1182/blood-2015-02-625251 · Cited by 53
“Among patients initiating chemotherapy, a disappointing median time-to-next treatment of,4 months is anticipated, and ;90% will require an alternative therapy within 1 year of treatment initiation.(2) Responses with biological response modifiers and histone deacetylase inhibitors, although superior to conventional che…”
Metadata
- Authors
- Hughes, C. F. M., Khot, A., McCormack, C., Lade, S., Westerman, D. A., Twigger, R., Buelens, O., Newland, K., Tam, C., Dickinson, M., Ryan, G., Ritchie, D., Wood, C., & Prince, H. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-01-01
- Volume
- 125
- Issue
- 1
- Pages
- 71-81
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2045009458
- Cited by
- 226
- References
- 3
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. https://app.cochat.ai/papers/10.1182/blood-2014-07-588236
- The paper
- Hughes, C. F. M., Khot, A., McCormack, C., Lade, S., Westerman, D. A., Twigger, R., Buelens, O., Newland, K., Tam, C., Dickinson, M., Ryan, G., Ritchie, D., Wood, C., & Prince, H. M. (2015). Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. https://doi.org/10.1182/blood-2014-07-588236
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.